# Doravirine/Lamivudine (DOR/3TC) as a Maintenance ART in Comparison With Dolutegravir/Lamivudine (DTG/3TC) in PLWH Successfully

> **NCT06774872** · PHASE2 · RECRUITING · sponsor: **Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida** · enrollment: 408 (estimated)

## Conditions studied

- HIV-1-infection

## Interventions

- **DRUG:** Doravirine 100Mg Tab and Lamivudine 300 Mg Tab
- **DRUG:** Dolutegravir 50mg Tab and Lamivudine 300 Mg Tab

## Key facts

- **NCT ID:** NCT06774872
- **Lead sponsor:** Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-30
- **Primary completion:** 2027-01-15
- **Final completion:** 2028-06-15
- **Target enrollment:** 408 (ESTIMATED)
- **Last updated:** 2025-06-11

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06774872

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06774872, "Doravirine/Lamivudine (DOR/3TC) as a Maintenance ART in Comparison With Dolutegravir/Lamivudine (DTG/3TC) in PLWH Successfully". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06774872. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*